格隆汇12月29日丨四环医药(00460.HK)公告，12月29日耗资1000.9万港元回购800万股。 ...

智通财经APP讯，四环医药(00460)发布公告，于2025年12月29日斥资1000.88万港元回购800万股。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 關於四環醫藥 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 購回股份 此 乃 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司， 統 稱 為「本集團」）作 出 的 自 願 公 告。 本 公 司 董 事 會（「董事會」）謹 此 宣 佈，根 據 本 公 司 股 東 於 二 零 二 五 年 六 月 六 日 舉 行 之 股 東 周 年 大 會 上 授 出 之 一 般 購 回 授 權（「購回授權」），其 擬 行 使 其 權 利 以 於 適 當 時 候 從 公 開 市 場 購 回 股 份。 董 事 會 進 一 步 宣 佈，根 據 購 回 授 權，本 公 司 於 二 零 二 五 年 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 四環醫藥控股集團有限公司 呈交日期： 2025年12月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 00460 | 說明 | 面值港幣 0.01 元普通股 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫 ...

Core Insights - The recognition of Ms. Miao Guili as "CFO of the Year" reflects the effective implementation of the dual-driven strategy of "innovative drugs + medical aesthetics" at Four Rings Pharmaceutical during a critical transformation period [1] - The management team's understanding of industry trends is crucial for sustainable development and strategic adjustments in response to market uncertainties [1] Innovative Drug Business - The Chinese innovative drug industry is entering a golden period of high-quality development by 2025, supported by new policies and market dynamics [3] - In 2023, 69 innovative drugs were approved for market entry in China, marking a historical high, with oncology and metabolic diseases as key research areas [3] - Four Rings Pharmaceutical has successfully launched three drugs in its innovative drug segment, focusing on oncology and metabolic diseases, and is advancing its pipeline with significant products [4][5] Medical Aesthetics Business - The medical aesthetics sector of Four Rings Pharmaceutical is experiencing high-quality growth amid industry regulation, with new pricing guidelines reshaping the market landscape [7] - The Chinese medical aesthetics market has surpassed 300 billion yuan, with a projected compound annual growth rate exceeding 20% over the next five years [8] - Four Rings has established a competitive advantage in the medical aesthetics field with over 30 products in development, including various injectables and skin management devices [9] Market Position and Future Outlook - The company is gaining attention from brokerage firms, with many believing that it is undervalued and has significant potential for valuation recovery [11] - The dual-driven strategy in innovative drugs and medical aesthetics is expected to enhance the company's market value as it continues to realize its R&D achievements and expand globally [11]

Core Viewpoint - The "Annual Outstanding CFO" award recognizes financial leaders who have made significant contributions and demonstrated exceptional leadership within their companies [4] Group 1: Award Announcement - The "Annual Outstanding CFO" award ceremony will take place during the "Technology Empowerment · Capital Breakthrough" sharing session on December 22, featuring a list of notable companies [1] - Ten individuals from various companies have been awarded the "Annual Outstanding CFO" title, including representatives from Baize Medical, Le Comfort, Quantum Song, Meitu, SF Express, Sikao Education, Four Rings Pharmaceutical, Hong Kong and China Gas, New World Development, and Starry Commercial [1] Group 2: Evaluation Criteria - The selection process for the award involved multiple indicators such as strategic contribution, capital market operations, and corporate value creation, utilizing a rigorous evaluation procedure and quantitative data analysis [4] - The award aims to create a reference list of the most valuable listed companies and unicorns in the investment community, covering all listed companies on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

格隆汇12月22日｜格隆汇今日线上举办"科技赋能·资本破局"分享会。备受瞩目的卓越公司评选榜单隆 重揭晓。其中，格隆汇"金格奖"年度卓越公司评选中，四环医药(0460.HK)缪瑰丽荣获"年度卓越 CFO"奖项。 "年度卓越CFO"奖旨在表彰做出卓越贡献并展现出卓著领导力的企业财务领袖。CFO是企业财务管理的 核心角色，也是企业战略和经营的重要支持者。本次评选从战略贡献、资本市场运营、企业价值创造等 多个指标，通过严格的评审程序和定量数据分析，评选出最终的获奖者。 ...

Group 1 - The core viewpoint of the article highlights a significant rise in Hong Kong's innovative pharmaceutical stocks, with companies like InnoCare Pharma-B and Lepu Biopharma-B seeing increases of over 7% and 5% respectively, driven by the addition of 111 new drugs to the national medical insurance catalog, marking a record high in both quantity and proportion [1] - The new catalog includes 50 first-class new drugs, indicating a strong trend towards innovation in the pharmaceutical sector, which is expected to continue into 2026, focusing on "innovation + internationalization" as the core theme [1] - The Hang Seng Innovative Drug ETF (159316) has attracted significant capital, with a net inflow of 236 million yuan over the past 10 days, bringing its total size to 4.086 billion yuan, reflecting strong investor interest in the innovative drug sector [1] Group 2 - The article notes that the innovative drug industry is expected to maintain an upward trend, with a focus on companies that demonstrate global competitiveness and successful commercialization [1] - The medical device industry is also experiencing a phase of easing factors, with innovation and internationalization accelerating, suggesting potential improvements by 2026 [1] - The Hang Seng Innovative Drug ETF is the only product tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which excludes CXO companies and focuses on core enterprises in the innovative drug industry, providing investors with a convenient tool for exposure to leading companies [1]

四环医药(00460)发布公告，于2025年12月18日，受托人已就股份奖励计划于市场上购买合共900万股公 司股份。 ...

格隆汇12月18日丨四环医药(00460.HK)公告，于2025年12月18日，受托人已就股份奖励计划于市场上购 买合共900万股公司股份，每股购买股份平均代价约1.2271港元。 ...